


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:04:14Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406537" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406537</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>vetres</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Res</journal-id><journal-id journal-id-type="iso-abbrev">Vet Res</journal-id><journal-id journal-id-type="pmc-domain-id">892</journal-id><journal-id journal-id-type="pmc-domain">vetres</journal-id><journal-title-group><journal-title>Veterinary Research</journal-title></journal-title-group><issn pub-type="ppub">0928-4249</issn><issn pub-type="epub">1297-9716</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406537</article-id><article-id pub-id-type="pmcid-ver">PMC12406537.1</article-id><article-id pub-id-type="pmcaid">12406537</article-id><article-id pub-id-type="pmcaiid">12406537</article-id><article-id pub-id-type="pmid">40898350</article-id><article-id pub-id-type="doi">10.1186/s13567-025-01608-7</article-id><article-id pub-id-type="publisher-id">1608</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Characterization of an enterococcal phage endolysin as a potential antimicrobial agent against <italic toggle="yes">Streptococcus suis</italic></article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Wang</surname><given-names initials="J">Jing</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Liu</surname><given-names initials="Y">Yaowei</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liang</surname><given-names initials="S">Siyu</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lu</surname><given-names initials="X">Xiaofeng</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="Q">Qiu</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fan</surname><given-names initials="C">Cuilong</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="W">Wanjiang</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Liu</surname><given-names initials="S">Siguo</given-names></name><address><email>liusiguo@caas.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2041-2208</contrib-id><name name-style="western"><surname>Xie</surname><given-names initials="F">Fang</given-names></name><address><email>xiefang@caas.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0313jb750</institution-id><institution-id institution-id-type="GRID">grid.410727.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0526 1937</institution-id><institution>State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, </institution><institution>Chinese Academy of Agricultural Sciences, </institution></institution-wrap>Harbin, China </aff></contrib-group><author-notes><fn fn-type="com"><p>Handling editor: Marcelo Gottschalk</p></fn></author-notes><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>56</volume><issue-id pub-id-type="pmc-issue-id">478407</issue-id><elocation-id>174</elocation-id><history><date date-type="received"><day>29</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>4</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="13567_2025_Article_1608.pdf"/><abstract id="Abs1"><p id="Par1"><italic toggle="yes">Streptococcus suis</italic>, an important zoonotic pathogen capable of transmission from pigs to humans, represents a critical threat to both public health and the global pork industry. The increasing prevalence of multidrug-resistant&#160;<italic toggle="yes">S. suis</italic>&#160;strains, coupled with their ability to form biofilms, has necessitated the development of alternative antimicrobial strategies. In this study, we characterized the therapeutic potential of Ply113, an endolysin derived from an <italic toggle="yes">Enterococcus faecium</italic> phage, against <italic toggle="yes">S. suis</italic>. Ply113 has shown potent bactericidal activity against <italic toggle="yes">S. suis</italic> in vitro, with rapid time-kill characteristics and broad-spectrum efficiency against clinically prevalent serotypes (2, 3, 4, 7, and 9). Transmission electron microscopy analysis revealed that Ply113 induced distinct morphological alterations in <italic toggle="yes">S. suis</italic>, including cell wall disintegration and cytoplasmic leakage. This endolysin exhibited anti-biofilm functionality, eradicating biofilms formed by clinical strain of <italic toggle="yes">S. suis</italic> in a concentration-dependent manner. In murine models of bacteremia, a single administration of Ply113 provided complete protection against lethal <italic toggle="yes">S. suis</italic> infection, significantly decreasing the bacterial burden in the liver and spleen and attenuating organ injury. Additionally, Ply113 has been shown to be safe for mice, with no adverse effects. Taken together, our findings indicate that Ply113 is a promising alternative antimicrobial agent for combating biofilm-related infections caused by <italic toggle="yes">S. suis</italic>.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic toggle="yes">Streptococcus suis</italic></kwd><kwd>phage</kwd><kwd>endolysin</kwd><kwd>antibacterial activity</kwd><kwd>anti-biofilm activity</kwd></kwd-group><funding-group><award-group><funding-source><institution>Central Public-interest Scientific Institution Basal Research Fund</institution></funding-source><award-id>1610302025002</award-id><principal-award-recipient><name name-style="western"><surname>Xie</surname><given-names>Fang</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; L&#8217;Institut National de Recherche en Agriculture, Alimentation et Environnement (INRAE) 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2"><italic toggle="yes">Streptococcus suis</italic> is a Gram-positive bacterium that causes clinical conditions such as septicemia, meningitis, arthritis, endocarditis, and pneumonia in pigs, which is responsible for considerable economic loss in the porcine industry [<xref ref-type="bibr" rid="CR1">1</xref>]. <italic toggle="yes">S. suis</italic> is the most frequently isolated bacterial pathogen in pig farms globally, and its prevalence exceeds 80% in some countries and regions [<xref ref-type="bibr" rid="CR2">2</xref>&#8211;<xref ref-type="bibr" rid="CR5">5</xref>]. As an emerging zoonotic pathogen, <italic toggle="yes">S. suis</italic> can be transmitted to humans via the consumption of contaminated pork products or close contact with sick or carrier pigs. <italic toggle="yes">S. suis</italic> poses a significantly high risk to humans, especially individuals with compromised immune systems<italic toggle="yes">,</italic> leading to meningitis and streptococcal toxic shock-like syndrome, which are frequently accompanied by high mortality rates in severe cases or lifelong sequelae following survival, such as deafness [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Although human <italic toggle="yes">S. suis</italic> infections are considered sporadic, two large-scale outbreaks of human infections have been documented in China, indicating the&#160;public&#160;health&#160;threat posed by this pathogen [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par3">According to the antigenic differences in the capsular polysaccharide (CPS), <italic toggle="yes">S. suis</italic> can be categorized into 29 serotypes (1&#8211;19, 21, 23&#8211;25, 27&#8211;31, 1/2) [<xref ref-type="bibr" rid="CR10">10</xref>]. Although the distribution of <italic toggle="yes">S. suis</italic> serotypes from clinical cases may differ across geographic locations, <italic toggle="yes">S. suis</italic> serotype 2 is commonly regarded as the most prevalent serotype worldwide and is associated with the majority of severe infections in pigs and humans, particularly in Asian countries [<xref ref-type="bibr" rid="CR11">11</xref>]. Additionally, serotypes 3, 4, 7, and 9 are the predominant prevalent serotypes worldwide [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Currently, antibiotics remain the mainstay treatment options for managing <italic toggle="yes">S. suis</italic> infections. However, the emergence of antibiotic-resistant strains of <italic toggle="yes">S. suis</italic>, especially multidrug-resistant isolates, has made controlling these infections a major challenge in the pig industry [<xref ref-type="bibr" rid="CR12">12</xref>]. Although vaccines may represent a rational alternative to antibiotics, the high genetic and phenotypic variability of <italic toggle="yes">S. suis</italic> poses significant difficulties in the development of a universal vaccine [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Given these challenges, there is an urgent need to develop novel antimicrobial approaches against the growing threat posed by antibiotic-resistant strains of <italic toggle="yes">S. suis</italic>.</p><p id="Par4">Endolysins are phage-derived enzymatic proteins biosynthesized during the terminal phase of the phage replication cycle that function to degrade bacterial peptidoglycan structures and facilitate the release of progeny phages [<xref ref-type="bibr" rid="CR15">15</xref>]. Thus, exogenous delivery of purified endolysins to peptidoglycan substrates induces &#8220;lysis from without&#8221; with high bactericidal efficiency and has sparked interest as a prospective antibacterial agent [<xref ref-type="bibr" rid="CR16">16</xref>]. The evolutionary conservation of peptidoglycan as the enzymatic substrate for endolysins confers a remarkably low possibility of resistance development, which is a critical advantage in combating multidrug-resistant bacteria [<xref ref-type="bibr" rid="CR17">17</xref>]. Various clinical trials have demonstrated the safety and efficacy of phage endolysins, which aligns with extensive evidence from animal models [<xref ref-type="bibr" rid="CR18">18</xref>]. Furthermore, endolysins with enhanced stability and broad-spectrum bactericidal activity show increased potential for clinical application [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. To date, only temperate phages infecting <italic toggle="yes">S. suis</italic> have been isolated [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], limiting the development of phages as a therapeutic approach against <italic toggle="yes">S. suis</italic>. Thus, it is critical to explore the possible application of phage-derived endolysins as the alternative antimicrobial agent for combating <italic toggle="yes">S. suis</italic>.</p><p id="Par5">Our previous study identified the endolysin Ply113 from <italic toggle="yes">Enterococcus faecium</italic> phage and demonstrated its superior bactericidal activity against <italic toggle="yes">E. faecium</italic>, <italic toggle="yes">Enterococcus faecalis, and Staphylococcus aureus</italic>. Ply113 contains an N-terminal NlpC/P60 catalytic domain and a C-terminal SH3b domain for cell wall binding. Moreover, Ply113 exhibited favorable stability under various temperature and salinity conditions, indicating its potential as a promising antimicrobial agent [<xref ref-type="bibr" rid="CR22">22</xref>]. In the present study, we investigated the bactericidal activity of Ply113 against <italic toggle="yes">S. suis</italic> in vitro. Moreover, the effects of Ply113 on <italic toggle="yes">S. suis</italic> biofilm disruption were assessed. The therapeutic efficacy of Ply113 against lethal <italic toggle="yes">S. suis</italic> infection in vivo was further evaluated in a murine bacteremia model.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Bacterial strains and protein expression</title><p id="Par6">All <italic toggle="yes">S. suis</italic> strains used in this study were routinely grown at 37&#160;&#176;C under 5% CO<sub>2</sub> in tryptone soy broth (TSB) or tryptone soy agar (TSA; Bacto&#8482;, Becton Dickinson) supplemented with 5% newborn bovine serum unless otherwise specified. The <italic toggle="yes">S. suis</italic> 05ZYH33 strain, a highly virulent strain of serotype 2, was isolated from a clinical patient during the 2005 Sichuan outbreak in China (GenBank&#8482; accession no. <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="CP000407.1">CP000407.1</ext-link>). Other <italic toggle="yes">S. suis</italic> isolates were obtained from different diseased pigs and were identified as serotype 2 (6B, 449&#160;T, S8, S123, JL8F strains), serotype 3 (1518, A21, HLJ01, F32), serotype 4 (M17, NMG02, Y8, GN12), serotype 7 (NY7, G62, P76, L10), and serotype 9 (HN21, GZ-2, NF01, E05) using 16S rRNA sequencing analysis and serotyping as described previously [<xref ref-type="bibr" rid="CR23">23</xref>]. The Ply113 endolysin was expressed in the <italic toggle="yes">Escherichia coli</italic> strain BL21(DE3) and purified via Ni-affinity chromatography as described previously [<xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec4"><title>Bactericidal assay</title><p id="Par7">The bactericidal activity of Ply113 against <italic toggle="yes">S. suis</italic> strains was measured as a reduction in colony-forming unit (CFU) as previously described [<xref ref-type="bibr" rid="CR24">24</xref>]. <italic toggle="yes">S. suis</italic> was grown at 37&#160;&#176;C until it reached the logarithmic growth phase. The bacterial culture was centrifuged at 3500&#8201;&#215;&#8201;<italic toggle="yes">g</italic> for 10&#160;min, washed three times, and then resuspended in sterile phosphate-buffered saline (PBS, pH 7.4). The concentration was adjusted to approximately 5&#8201;&#215;&#8201;10<sup>7</sup>&#160;CFU/mL. To assess the impact of concentration on the bactericidal activity of Ply113 endolysin, bacterial suspensions of <italic toggle="yes">the S. suis</italic> 05ZYH33 strain were treated with Ply113 at different concentrations (0&#8211;16&#160;&#181;g/mL) for 1&#160;h at 37&#160;&#176;C. For time-kill assays, bacterial suspensions of the <italic toggle="yes">S. suis</italic> 05ZYH33 strain were treated with 16&#160;&#181;g/mL Ply113 for different durations (0&#8211;60&#160;min) at 37&#160;&#176;C. The samples were serially diluted tenfold in PBS before being distributed onto TSA plates for determination of viable counts. As a negative control, bacteria were treated with PBS under the same conditions. The experiments were performed in technical triplicates.</p></sec><sec id="Sec5"><title>Determination of Ply113 antimicrobial spectrum</title><p id="Par8">CFU reduction assays were used to determine the lytic activity of Ply113 against different <italic toggle="yes">S. suis</italic> strains. Briefly, the strains were cultured at 37&#160;&#176;C until they reached an optical density of 0.6 at 600&#160;nm (OD<sub>600</sub> nm), after which they were washed and resuspended in sterile PBS. Ply113 was added to the bacterial solution at a final concentration of 16&#160;&#181;g/mL and incubated at 37&#160;&#176;C for 1&#160;h. As a negative control, bacteria were treated with PBS buffer under the same conditions. The experiment was performed in technical triplicates.</p></sec><sec id="Sec6"><title>Transmission electron microscopy</title><p id="Par9">The <italic toggle="yes">S. suis</italic> 05ZYH33 strain was grown at 37&#160;&#176;C until the logarithmic growth phase was reached. <italic toggle="yes">S. suis</italic> cells were washed with PBS and treated with different concentrations of Ply113 (0&#8211;4&#160;&#181;g/mL) for 30&#160;min at 37&#160;&#176;C. Bacterial cells treated with PBS under the same conditions were used as a negative control. The bacterial cells were fixed with glutaraldehyde for 12&#160;h at 4&#160;&#176;C, incubated with 1% osmium tetroxide for 2&#160;h at 4&#160;&#176;C, and dehydrated in acetone. The fixed samples were subsequently immersed in epoxy resin for an overnight period and polymerized at high temperature for 48&#160;h. Ultrathin Sections&#160;(65&#8211;70&#160;nm thick) were sliced and placed on copper grids. Following staining with uranyl acetate and lead citrate, changes in bacterial morphology were observed using a transmission electron microscopy (Hitachi, Tokyo, Japan).</p></sec><sec id="Sec7"><title>Biofilm assays</title><p id="Par10">A crystal violet assay was used to assess the effectiveness of Ply113 on <italic toggle="yes">S. suis</italic> biofilm as previously described [<xref ref-type="bibr" rid="CR25">25</xref>]. <italic toggle="yes">S. suis</italic> JL8F, a strong biofilm-forming strain, was grown in TSB medium supplemented with 5% newborn bovine serum until it reached the logarithmic growth phase and then diluted 100-fold in TSB medium. One hundred microliters of bacterial solution (10<sup>6</sup>&#160;CFU/mL) was added to each well of a 96-well polypropylene microtiter plate (Corning, NY, USA) and incubated at 37&#160;&#176;C for 24&#160;h to allow biofilm formation. The wells were washed with PBS to remove the planktonic cells. Next, the preformed biofilms were treated with different concentrations of Ply113 (0&#8211;16&#160;&#956;g/mL). Following incubation for 2&#160;h, each well was carefully washed with PBS, and the residual biofilms were fixed with methanol and stained with 1% crystal violet for 15&#160;min. After staining, the attached crystal violet was dissolved in 33% glacial acetic acid. Biomass was quantified by measuring absorbance of each well at OD<sub>570 nm</sub> using an EnVision Multimode Plate Reader (PerkinElmer, Waltham, USA). To assess the bactericidal efficiency of Ply113 against established biofilms of <italic toggle="yes">S. suis</italic>, the quantification of viable cells in biofilm after 2&#160;h of Ply113 treatment was performed using plate colony counts [<xref ref-type="bibr" rid="CR26">26</xref>]. The experiment was performed in technical triplicates with three biological replicates for each sample.</p></sec><sec id="Sec8"><title>Confocal laser scanning microscopy</title><p id="Par11">The biofilm samples for confocal laser scanning microscopy (CLSM) observation were prepared according to a previous procedure with some modifications [<xref ref-type="bibr" rid="CR27">27</xref>]. A total of 2&#8201;&#215;&#8201;10<sup>6</sup>&#160;CFU of <italic toggle="yes">S. suis</italic> JL8F was added to glass-bottom microwell dishes (Nest, Wuxi, China). Following 24&#160;h of incubation at 37&#160;&#176;C, the biofilms were washed to remove the planktonic cells and treated with Ply113 at a concentration of 16&#160;&#956;g/mL and further incubated for 2&#160;h. Mature biofilms treated with PBS served as control. The biofilms were subsequently washed and stained for 20&#160;min in the dark at room temperature with a LIVE/DEAD&#8482; BacLight&#8482; Bacterial Viability Kit (Invitrogen&#8482;, Thermo Fisher, USA). For exopolysaccharide visualization, biofilms were stained with Alexa Fluor 350-labeled Concanavalin A (Invitrogen&#8482;, Thermo Fisher, USA). Biofilm images were acquired using a confocal scanning laser microscope (Zeiss LSM 800, Jena, Germany). Quantification of biofilm was analyzed for the bio-volume and thickness using the COMSTAT software [<xref ref-type="bibr" rid="CR28">28</xref>]. Quantification of area stained for exopolysaccharide was performed using ImageJ software [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec9"><title>Experimental animals</title><p id="Par12">All the mouse experiments were conducted according to the Guide for the Care and Use of Laboratory Animals of the Ministry of Science and Technology of the People&#8217;s Republic of China. The procedure for the animal experiments in this study was approved by the Animal Ethics Committee of the Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences (Approval No. HVRI-IACUC-23121901GR). Specific-pathogen-free (SPF)-grade C57BL/6 mice (6&#160;weeks old) were procured from Vital River Experimental Animal Technology Co., Ltd. (Beijing, China) and housed under a 12-h light/dark cycle in individually ventilated cages with free access to standard animal food and water.</p></sec><sec id="Sec10"><title>Toxicity to C57BL/6 mice</title><p id="Par13">Fifteen 6-week-old C57BL/6 mice were randomly divided into three groups, with five mice in each group (<italic toggle="yes">n</italic>&#8201;=&#8201;5). In group 1, five mice received an intraperitoneal injection of 8&#160;mg/kg Ply113 in 100&#160;&#181;L of PBS, whereas five mice in group 2 received an injection of 16&#160;mg/kg Ply113. The control group was injected with 100 &#181;L of PBS. After administration, the mice in each group were observed for clinical signs, such as lethargy, loss of appetite, ruffled fur, hunched posture, paralysis, and weighed daily for 10&#160;days. After that, the mice were euthanized, and the organs were collected to examine changes in gross lesions.</p></sec><sec id="Sec11"><title>Therapeutic effect of Ply113 in vivo</title><p id="Par14">A murine bacteremia model of <italic toggle="yes">S. suis</italic> was constructed as previously described with some modifications [<xref ref-type="bibr" rid="CR30">30</xref>]. Briefly, C57BL/6 mice (6&#160;weeks old) were injected intraperitoneally with 100 &#956;L of 8&#8201;&#215;&#8201;10<sup>8</sup>&#160;CFU log-phase <italic toggle="yes">S. suis</italic> 05ZYH33, and then the mice were randomly divided into four groups, with ten mice in each group (<italic toggle="yes">n</italic>&#8201;=&#8201;10). Two hours after infection, groups 1, 2, and 3 were administered Ply113 at therapeutic doses of 2, 4, and 8&#160;mg/kg, respectively. The control group was injected with 100 &#181;L of PBS. Mortality following intraperitoneal challenge was monitored for 7&#160;days.</p><p id="Par15">For bacterial load detection, C57BL/6 mice (6&#160;weeks old) were infected with 8&#8201;&#215;&#8201;10<sup>7</sup>&#160;CFU of <italic toggle="yes">S. suis</italic> 05ZYH33 and then administered 8&#160;mg/kg Ply113 at 2&#160;h post-infection. The control group was administered 100 &#181;L of PBS. The mice in each group were euthanized at 24&#160;h after infection, and the liver and spleen were aseptically removed, weighed and homogenized. The homogenate was then serially diluted in PBS and plated on TSA plates to calculate the number of bacterial CFUs per milliliter in each sample. For histopathological analysis, the liver and spleen were removed and fixed in 4% paraformaldehyde. The dehydrated tissues were embedded in paraffin and subsequently further sliced into 4&#160;&#956;m-thick sections. The paraffin sections were dewaxed and stained with hematoxylin and eosin (H&amp;E). The pathological changes in each tissue sample were evaluated using light microscopy.</p></sec><sec id="Sec12"><title>Statistical analysis</title><p id="Par16">GraphPad Prism 9.0 (GraphPad Software, San Diego, CA) was used for statistical analysis and graphing. The data are expressed as the mean&#8201;&#177;&#8201;standard deviation (SD). Statistical significance was determined via one-way analysis of variance (ANOVA) or an unpaired <italic toggle="yes">t</italic> test. <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 was considered significant (*<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001).</p></sec></sec><sec id="Sec13"><title>Results</title><sec id="Sec14"><title>Ply113 displays bactericidal activity against <italic toggle="yes">S. suis</italic></title><p id="Par17">To evaluate the bactericidal activity of Ply113 in vitro, various concentrations of Ply113 (0&#8211;16&#160;&#181;g/mL) were incubated with <italic toggle="yes">S. suis</italic>, and the number of viable bacteria was calculated. As shown in Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref>A, Ply 113 caused a gradual decrease in the number of viable bacteria in a dose-dependent manner, with a 1.44 log<sub>10</sub> reduction at 2&#160;&#181;g/mL and a 4.68 log<sub>10</sub> reduction at 16&#160;&#956;g/mL. The results of the time-killing assay also revealed the effective bactericidal activity of Ply113 against <italic toggle="yes">S. suis</italic> within 60&#160;min at a concentration of 16&#160;&#956;g/mL (Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref>B). The number of viable bacteria decreased by 2.20 log<sub>10</sub> within 10&#160;min and 3.83 log<sub>10</sub> within 30&#160;min. After treatment for 60&#160;min, Ply113 caused a reduction of 4.74 log<sub>10</sub> (Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref>B). The bactericidal activities of Ply113 against the main prevalent serotypes of <italic toggle="yes">S. suis</italic> isolates, including serotypes 2, 3, 4, 7, and 9, were subsequently determined in vitro. As shown in Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref>C, despite variations in lytic efficiency, Ply113 was able to kill all <italic toggle="yes">S. suis</italic> strains used in this study (22/22), exhibiting broad bactericidal activity. These results suggest that Ply113 is highly active against <italic toggle="yes">S. suis</italic> strains in vitro.<fig id="Fig1" position="float" orientation="portrait"><label>Figure&#160;1</label><caption><p><bold>Lytic spectrum and bactericidal activity of Ply113 against</bold>
<bold><italic toggle="yes">S. suis</italic></bold>. <bold>A</bold> Concentration-dependent killing efficacy of Ply113. Bacterial cells were treated with various concentrations of Ply113 (0&#8211;16&#160;&#956;g/mL) for 60&#160;min before being diluted and plated on TSA plates for CFU counting. The data are presented as the mean&#8201;&#177;&#8201;SD from three independent tests. Statistical significance was calculated via one-way analysis of variance (ANOVA). ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; ns, not significant. <bold>B</bold> Time-dependent killing curves of Ply113. The bacterial cells were treated with 16&#160;&#956;g/mL Ply113 for different durations before being diluted and plated on TSA plates for CFU counting. <bold>C</bold> Bactericidal activities of Ply113 against various serotypes of <italic toggle="yes">S. suis</italic>. Each strain was treated with 16&#160;&#956;g/mL Ply113 or PBS for 60&#160;min. The reduction in bacterial CFUs was used to assess the bactericidal efficacy of Ply113 against <italic toggle="yes">S. suis</italic> strains.</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="13567_2025_1608_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec15"><title>Ply113 destroys the cell morphology of <italic toggle="yes">S. suis</italic></title><p id="Par18">To investigate the effects of Ply113 on the cell morphology of <italic toggle="yes">S. suis</italic>, the bacterial suspensions of the <italic toggle="yes">S. suis</italic> 05ZYH33 strain were treated with Ply113 at lower concentrations (0&#8211;4&#160;&#181;g/mL) and observed via transmission electron microscopy. As shown in Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref>, <italic toggle="yes">S. suis</italic> 05ZYH33 treated with PBS displayed an intact spherical shape with well-defined cell envelope structures. However, evident cell perforation and deformation were observed in <italic toggle="yes">S. suis</italic> treated with Ply113. At 2&#160;&#181;g/mL, Ply113 was found to induce rupture of the cytoplasmic membrane and cell wall, resulting in a modest number of bacterial ghosts devoid of cytoplasmic components (Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Increasing the concentration of Ply113 to 4&#160;&#181;g/mL led to a greater proportion of bacterial ghosts and more severe ultrastructural damage (Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Figure&#160;2</label><caption><p><bold>Morphological changes in</bold>
<bold><italic toggle="yes">S. suis</italic></bold><bold> after Ply113 treatment</bold>. TEM analysis of <italic toggle="yes">S. suis</italic> 05ZYH33 in the logarithmic phase or after exposure to various concentrations of Ply113 (2 and 4&#160;&#956;g/mL) for 30&#160;min at 37&#160;&#176;C. Scale bar, 500&#160;&#956;m.</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="13567_2025_1608_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec16"><title>Ply113 exhibits anti-biofilm activity against <italic toggle="yes">S. suis</italic></title><p id="Par19">To investigate the antibiofilm activity of Ply113, the <italic toggle="yes">S. suis</italic> JL8F strain was chosen because of its ability to produce strong biofilms. A crystal violet staining assay was performed to examine the ability of Ply113 to eliminate established biofilms. As shown in Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref>A, Ply113 effectively reduced the biomass of 24&#160;h-old biofilms established by <italic toggle="yes">S. suis</italic> in a concentration-dependent manner. Treatment with 4&#160;&#181;g/mL Ply113 at 37&#160;&#176;C for 2&#160;h eliminated 66.9% of the biofilm biomass, whereas treatment with 16&#160;&#181;g/mL Ply113 eliminated nearly all the biofilm biomass (93.2%). In addition, treatment with Ply113 for 2&#160;h reduced the number of viable bacteria in <italic toggle="yes">S. suis</italic> biofilm, with a 0.98 log<sub>10</sub> reduction at 4&#160;&#181;g/mL and a 2.19 log<sub>10</sub> reduction at 16&#160;&#956;g/mL (Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref>B).<fig id="Fig3" position="float" orientation="portrait"><label>Figure&#160;3</label><caption><p><bold>Effects of Ply113 on</bold>
<bold><italic toggle="yes">S. suis</italic></bold><bold> established biofilms</bold>. <bold>A</bold> Ply113 antibiofilm activity quantification by crystal violet staining. The preformed <italic toggle="yes">S. suis</italic> biofilms were treated with different concentrations of Ply113 (0&#8211;16&#160;&#956;g/mL) at 37&#160;&#176;C for 2&#160;h. <bold>B</bold> The number of viable bacteria in biofilms after treatment with different concentrations of Ply113 (0&#8211;16&#160;&#956;g/mL) at 37&#160;&#176;C for 2&#160;h. The data are presented as the mean&#8201;&#177;&#8201;SD from three independent tests with three biological replicates for each sample. Statistical significance was calculated via one-way ANOVA. ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001. <bold>C</bold> CLSM imaging of SYTO9&#8211;PI-stained <italic toggle="yes">S. suis</italic> biofilms following treatment with Ply113 at a concentration of 16&#160;&#956;g/mL. <bold>D</bold> COMSTAT analysis of the corresponding biofilm CLSM images. <bold>E</bold> CLSM imaging of <italic toggle="yes">S. suis</italic> biofilms stained with Alexa Fluor 350-labelled Concanavalin A (exopolysaccharides, blue) in 24-h-established biofilms followed by 2&#160;h treatment of Ply113. Scale bar, 20&#160;&#956;m <bold>F</bold> Quantification of fluorescence area of exopolysaccharides by ImageJ analysis. ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001 significance was determined by comparison to the untreated control. Error bars represent the standard deviation of the data set (<italic toggle="yes">n</italic>&#8201;=&#8201;4).</p></caption><graphic id="MO3" position="float" orientation="portrait" xlink:href="13567_2025_1608_Fig3_HTML.jpg"/></fig></p><p id="Par20">The effects of Ply113 on the biofilms of the <italic toggle="yes">S. suis</italic> JL8F strain were evaluated by the CLSM observation. CLSM images showed that <italic toggle="yes">S. suis</italic> JL8F without Ply113 treatment formed a mature biofilm with an intact multilayered three-dimensional structure (Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref>C). After 2&#160;h of treatment, Ply113 efficiently eliminated 24-h-old biofilms, as evidenced by the structural destruction of the majority of the biofilms (Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref>C). The bio-volume and thickness of <italic toggle="yes">S. suis</italic> biofilm were assessed using COMSTAT software. The analysis showed that the Ply113-treated biofilm exerted a decrease in biomass and mean thickness when compared to the control biofilm (Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref>D). Furthermore, exopolysaccharides, as key constituents of the biofilm extracellular matrix, are essential for maintaining mature biofilm structure. To determine the effect of Ply113 on <italic toggle="yes">S. suis</italic> biofilm extracellular matrix, <italic toggle="yes">S. suis</italic> biofilms after Ply113 treatment were stained by Alexa Fluor 350-labeled Concanavalin A to visualize the biofilm exopolysaccharides. As shown in Figures&#160;<xref rid="Fig3" ref-type="fig">3</xref>E and F, there was a substantial reduction in the contents of exopolysaccharides in the biofilms treated with Ply113 compared to the control biofilm. These results suggested that Ply113 could eliminate <italic toggle="yes">S. suis</italic> biofilms through killing biofilm-derived cells and disrupting the extracellular matrix.</p></sec><sec id="Sec17"><title>Ply113 shows no toxicity to C57BL/6 mice</title><p id="Par21">To test the toxicity of Ply113 to mice, 6-week-old healthy C57BL/6 mice were intraperitoneally administered the therapeutic dose (8&#160;mg/kg) or twice the therapeutic dose (16&#160;mg/kg) of Ply113, and their overall health was evaluated for ten days. Neither the 8&#160;mg/kg nor the 16&#160;mg/kg doses caused death during the monitoring period. All the mice in each group maintained normal health and diet, as evidenced by the progressive increase in body weight over the observation period (Figure&#160;<xref rid="Fig4" ref-type="fig">4</xref>A). The organs of the mice in each group were collected 10&#160;days after injection to determine whether they had incurred any toxic damage. As shown in Figure&#160;<xref rid="Fig4" ref-type="fig">4</xref>B, no gross lesions were observed in the lungs, livers, kidneys, or spleens of the mice injected with either the 8&#160;mg/kg or the 16&#160;mg/kg dose. These results suggested that Ply113 had no adverse effects on the health status of the mice.<fig id="Fig4" position="float" orientation="portrait"><label>Figure&#160;4</label><caption><p><bold>Toxicity of Ply113 to mice</bold>. <bold>A</bold> Variation in the body weight of the mice after P113 administration. The body weights of the mice in each group were recorded over 10&#160;days after intraperitoneal injection of Ply 113 (8 and 16&#160;mg/kg). The data are presented as the mean&#8201;&#177;&#8201;SD. <bold>B</bold> Organs of mice after treatment with Ply 113 (8 and 16&#160;mg/kg) or PBS. Scale bars, 10&#160;mm. No gross lesion changes were observed in the lungs, livers, kidneys, or spleens of the mice from each group.</p></caption><graphic id="MO4" position="float" orientation="portrait" xlink:href="13567_2025_1608_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec18"><title>Ply113 rescues mice against lethal <italic toggle="yes">S. suis</italic> infection</title><p id="Par22">The in vivo therapeutic potential of Ply113 was evaluated using a murine bacteremia model. Intraperitoneal injection of 8&#8201;&#215;&#8201;10<sup>8</sup>&#160;CFU/mouse of <italic toggle="yes">S. suis</italic> 05ZYH33 was sufficient to cause 100% mortality within 24&#160;h post-infection. Mice infected with <italic toggle="yes">S. suis</italic> for 2&#160;h were treated with various doses of Ply113 (2, 4, and 8&#160;mg/kg). All the mice in the control group treated with PBS died within 24&#160;h post-infection. However, Ply113 displayed a dose-dependent therapeutic effect (Figure&#160;<xref rid="Fig5" ref-type="fig">5</xref>A). Treatment with a single dose of Ply113 (2&#160;mg/kg) protected 20% of the mice, whereas injection of 4&#160;mg/kg Ply113 rescued 60% of the mice. Ply113 at a dose of 8&#160;mg/kg was capable of completely rescuing the mice from death, with a 100% survival rate (Figure&#160;<xref rid="Fig5" ref-type="fig">5</xref>A).<fig id="Fig5" position="float" orientation="portrait"><label>Figure&#160;5</label><caption><p><bold>Therapeutic efficacy of Ply113 in a mouse bacteremia model.</bold>
<bold>A</bold> Survival of mice infected with <italic toggle="yes">S. suis</italic> 05ZYH33 and treated with various doses of Ply113 (2, 4, and 8&#160;mg/kg). Bacterial loads in (<bold>B</bold>) livers and (<bold>C</bold>) spleens from mice infected with <italic toggle="yes">S. suis</italic> and treated with 8&#160;mg/kg Ply113. The data are presented as the means&#8201;&#177;&#8201;SD from five mice. Statistical significance was calculated via unpaired<italic toggle="yes"> t</italic> tests. **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001.</p></caption><graphic id="MO5" position="float" orientation="portrait" xlink:href="13567_2025_1608_Fig5_HTML.jpg"/></fig></p></sec><sec id="Sec19"><title>Ply113 reduces bacterial burden and attenuates organ injury in <italic toggle="yes">S. suis</italic>-infected mice</title><p id="Par23">The in vivo antibacterial efficacy of Ply113 was further examined by comparing the bacterial burdens in the lungs and spleens of the mice in the PBS- and Ply113-treated groups. C57BL/6 mice were infected with 8&#8201;&#215;&#8201;10<sup>7</sup>&#160;CFU of <italic toggle="yes">S. suis</italic> 05ZYH33 and treated with 8&#160;mg/kg Ply113 or PBS as controls. After 24&#160;h of treatment, the liver and spleen from each mouse were excised and homogenized for bacterial burden quantification. As shown in Figures&#160;<xref rid="Fig5" ref-type="fig">5</xref>B and <xref rid="Fig5" ref-type="fig">C</xref>, bacterial counts in the liver and spleen were significantly different between mice treated with a single dose of Ply113 and those injected with PBS. Compared with the PBS control, Ply113 treatment reduced bacterial counts in the livers of <italic toggle="yes">S. suis</italic>-infected mice by 2.32 log<sub>10</sub> (Figure&#160;<xref rid="Fig5" ref-type="fig">5</xref>B). In addition, the bacterial loads in the spleens of Ply113-treated mice decreased by 2.10 log&#8321;&#8320; (Figure&#160;<xref rid="Fig5" ref-type="fig">5</xref>C).</p><p id="Par24">Histopathological analysis was conducted to evaluate the severity of tissue lesions in mice treated with Ply113 and PBS. As shown in Figure&#160;<xref rid="Fig6" ref-type="fig">6</xref>, healthy mice had normal tissue morphology, with no noticeable lesions. However, H&amp;E-stained sections revealed severe pathological damage to the tissues of <italic toggle="yes">S. suis</italic>-infected mice treated with PBS. The predominant pathological damage comprises multifocal patchy necrosis in the liver with extensive zones of hepatocyte degeneration and necrosis, as well as lymphoid depletion in the white pulp of the spleen, which manifests as diminished cellularity and lymphocyte necrosis (Figure&#160;<xref rid="Fig6" ref-type="fig">6</xref>). Compared with PBS treatment, Ply113 treatment noticeably alleviated the damage to the liver and spleen, with no obvious pathological injury detected (Figure&#160;<xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig6" position="float" orientation="portrait"><label>Figure&#160;6</label><caption><p><bold>Histopathological evaluation of organ injury in </bold><bold><italic toggle="yes">S. suis</italic></bold><bold>-infected mice treated with Ply113</bold>. Representative H&amp;E staining images of livers and spleens from healthy mice and infected mice subjected to PBS or Ply113 treatment. Scale bar, 50&#160;&#956;m.</p></caption><graphic id="MO6" position="float" orientation="portrait" xlink:href="13567_2025_1608_Fig6_HTML.jpg"/></fig></p></sec></sec><sec id="Sec20"><title>Discussion</title><p id="Par25"><italic toggle="yes">S. suis</italic> infection is a primary contributor to mortality and substantial economic losses in the pig industry worldwide. <italic toggle="yes">S. suis</italic> has a global distribution. Its prevalence exceeds 40% of pig farms in China, Canada, and Vietnam, and rises above 50% in Korea and Thailand [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Of particular concern is the increasing global trajectory of antibiotic resistance in <italic toggle="yes">S. suis</italic>. Currently, <italic toggle="yes">S. suis</italic> has limited resistance rates to &#946;-lactams, aminoglycosides, fluoroquinolones and sulfonamides, but high resistant rates (&gt;&#8201;80%) to tetracyclines, macrolides, and lincosamides worldwide [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Alarmingly, multidrug-resistant (MDR) strains now account for more than 90% of clinical isolates [<xref ref-type="bibr" rid="CR12">12</xref>], highlighting the critical necessity for developing novel therapeutic strategies.</p><p id="Par26">Phage-derived proteins, particularly endolysins, are emerging as groundbreaking therapeutic weapons against antimicrobial resistance. Our previous study demonstrated that Ply113, an endolysin derived from an <italic toggle="yes">E. faecium</italic> phage, exhibits potent bactericidal activity against notorious antibiotic-resistant pathogens, including <italic toggle="yes">E. faecium</italic>, <italic toggle="yes">E. faecalis</italic>, and <italic toggle="yes">S. aureus</italic> [<xref ref-type="bibr" rid="CR22">22</xref>]. The remarkable cross-species lytic capability of Ply113 prompted our investigation into its efficacy against <italic toggle="yes">S. suis</italic> in order to address its severe impact on swine health. In the present study, we found that Ply113 also exhibited potent bactericidal activity against <italic toggle="yes">S. suis</italic> strains. To date, several endolysins from enterococcal phages have been characterized and exhibited different lytic spectra. LysEFm5A, a lysin derived from an <italic toggle="yes">E. faecium</italic> bacteriophage, showed potent antibacterial activity against <italic toggle="yes">E. faecium</italic> but no observable activity against other tested bacterial species [<xref ref-type="bibr" rid="CR34">34</xref>]. Similarly, the LysEF-P10 lysin exhibited efficient bactericidal activity against <italic toggle="yes">E. faecalis</italic> strains while showing no efficacy against <italic toggle="yes">E. faecium</italic> [<xref ref-type="bibr" rid="CR35">35</xref>]. The ORF9 endolysin, derived from an <italic toggle="yes">E. faecalis</italic> phage, exhibited lytic activity against both <italic toggle="yes">E. faecalis</italic> and <italic toggle="yes">E. faecium</italic> but showed no activity against <italic toggle="yes">S. aureus</italic> or <italic toggle="yes">E. coli</italic> strains [<xref ref-type="bibr" rid="CR36">36</xref>]. In this study, the Ply113 endolysin exhibited potent bacteriolytic activity against three taxonomically distinct Gram-positive genera (<italic toggle="yes">E. faecium</italic>, <italic toggle="yes">E. faecali</italic>s, <italic toggle="yes">S. aureus</italic>, and <italic toggle="yes">S. suis</italic>), enhancing its therapeutic potential for controlling polymicrobial infections.</p><p id="Par27">Importantly, biofilms play crucial roles in <italic toggle="yes">S. suis</italic> infections, contributing significantly to bacterial persistence and immune evasion. In the biofilm state, <italic toggle="yes">S. suis</italic> not only evades phagocytosis by host immune cells but also suppresses the formation of neutrophil extracellular traps through its biofilm matrix [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Furthermore, compared with planktonic cells, biofilm-derived cells of <italic toggle="yes">S. suis</italic> was found to have a higher survival rate in host blood compared to planktonic cells [<xref ref-type="bibr" rid="CR37">37</xref>]. Once established in vivo, <italic toggle="yes">S. suis</italic> biofilms often lead to chronic infections that are notoriously difficult to eradicate [<xref ref-type="bibr" rid="CR39">39</xref>]. Notably, the majority of clinical <italic toggle="yes">S. suis</italic> isolates possess strong biofilm-forming capabilities [<xref ref-type="bibr" rid="CR40">40</xref>], highlighting the urgent need for biofilm-targeted therapeutic strategies. Although several endolysins that are active against <italic toggle="yes">S. suis</italic> have been characterized, experimental data regarding their efficacy against <italic toggle="yes">S. suis</italic> biofilms remain limited [<xref ref-type="bibr" rid="CR41">41</xref>&#8211;<xref ref-type="bibr" rid="CR45">45</xref>]. A previous study showed that LySMP endolysin could effectively eliminate 80% of the established biofilms of <italic toggle="yes">S. suis</italic> [<xref ref-type="bibr" rid="CR46">46</xref>]. Similarly, AVPL, an endolysin derived from <italic toggle="yes">Aerococcus viridans</italic> phage, has been found to be effective in both inhibiting and disrupting <italic toggle="yes">S. suis</italic> biofilms [<xref ref-type="bibr" rid="CR47">47</xref>]. In our study, Ply113 exhibited potent antibiofilm activity, even at concentrations as low as 4&#160;&#181;g/mL. Notably, Ply113 at 16&#160;&#181;g/mL achieved nearly complete biofilm eradication. These findings are consistent with the limited existing reports on endolysin-mediated biofilm control in <italic toggle="yes">S. suis</italic>, collectively supporting the potential of endolysins as an effective strategy against biofilm-associated infection caused by <italic toggle="yes">S. suis</italic>.</p><p id="Par28">Undoubtedly, safety represents a fundamental prerequisite for the clinical application of endolysins. Some preclinical investigations have consistently demonstrated that endolysins exhibit excellent safety properties, with no adverse effects in animal models [<xref ref-type="bibr" rid="CR48">48</xref>&#8211;<xref ref-type="bibr" rid="CR50">50</xref>]. This preclinical evidence has been further corroborated by human clinical trials. Specifically, the human phase 1 study of the SAL200 endolysin validated its safety, with participants experiencing only minor and temporary symptoms such as fatigue and myalgia, and no significant side events were noted [<xref ref-type="bibr" rid="CR51">51</xref>]. However, the safety profiles of various endolysin classes may differ, and some may pose risks to the host [<xref ref-type="bibr" rid="CR52">52</xref>]. To this end, we conducted safety assessments of Ply113 through high-dose administration in murine models. After receiving Ply113, the mice showed no observable signs of toxicity, maintained normal growth in body weight, and exhibited no histopathological alterations in major organs. These findings confirmed the favorable safety profile of Ply113, supporting its potential for therapeutic development. However, comprehensive safety assessments across multiple models are still needed. Another noteworthy concern in endolysin applications is their potential immunogenicity. Upon administration, endolysins may trigger immune responses, including the production of neutralizing antibodies and pro-inflammatory cytokines, which can significantly reduce their serum half-life [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. In clinical trials of the SAL200 endolysin, approximately 37% of subjects developed detectable antibodies following intravenous administration. Nevertheless, antimicrobial activity in blood was still observed at therapeutic doses not less than 1&#160;mg/kg [<xref ref-type="bibr" rid="CR51">51</xref>]. To address the issue of immunogenicity, researchers have proposed the strategy of engineering endolysins to improve their compatibility with human immune cells, thereby reducing host clearance of these heterologous proteins [<xref ref-type="bibr" rid="CR53">53</xref>]. Our future research may involve modifying Ply113 using alternative chimeric protein designs to minimize immune responses in vivo.</p><p id="Par29">The therapeutic potential of Ply113 was evaluated in a mouse model of <italic toggle="yes">S. suis</italic>-induced bacteremia. The therapeutic efficacy of Ply113 was dose-dependent, which is consistent with in vivo observations made with other endolysins, such as Cpl-1 and PlySK249 [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. In addition, Ply113 treatment significantly reduced bacterial loads in the liver and spleen of <italic toggle="yes">S. suis</italic>-infected mice, resulting in a reduction of more than 2 log<sub>10</sub>. Notably, a clinical trial using phage therapy for chronic otitis caused by <italic toggle="yes">Pseudomonas aeruginosa</italic> demonstrated that reducing the bacterial burden by 80% was sufficient for effective treatment [<xref ref-type="bibr" rid="CR56">56</xref>]. Given that Ply113 achieved&#8201;&gt;&#8201;95% bacterial clearance in vivo within 24&#160;h, it may be an ideal candidate for combating <italic toggle="yes">S. suis</italic> infections.</p><p id="Par30">In summary, the present results demonstrate that the Ply113 endolysin exhibits potent and broad-spectrum bactericidal activity against <italic toggle="yes">S. suis</italic>, efficiently lysing the most prevalent serotypes of <italic toggle="yes">S. suis</italic> (2, 3, 4, 7, and 9). This endolysin can significantly disrupt established biofilms of <italic toggle="yes">S. suis</italic>. Furthermore, a single administration of Ply113 significantly reduces the bacterial burden in systemically infected mice, alleviates organ pathological injury, and provides complete protection against lethal <italic toggle="yes">S. suis</italic> infections. These findings position Ply113 as a promising enzybiotic candidate for combating systemic <italic toggle="yes">S. suis</italic> infections. Future studies should focus on the optimization of Ply113 production and comprehensive preclinical evaluation in porcine models to advance therapeutic development.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Jing Wang and Yaowei Liu contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank Dr S. Wang and Dr Z. Zhang for their technical assistance with the TEM experiments and histopathological analysis.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>FX, SS, and WZ conceived and designed the experiments. JW, YL, SL, and XL performed the experiments. JW, QX, CF, and FX analyzed the data. JW, SS, and FX wrote the paper with input from all coauthors. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was supported by grants from the Central Public-interest Scientific Institution Basal Research Fund (No. 1610302025002).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>All data supporting the findings of this study are included in the article. Additional data are available from the corresponding authors upon request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par31">All animal experiments were approved by the Animal Ethics Committee of the Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences (Approval No. HVRI-IACUC-23121901GR) and were performed according to the Animal Welfare Agency Guidelines.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par32">The authors declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goyette-Desjardins</surname><given-names>G</given-names></name><name name-style="western"><surname>Auger</surname><given-names>JP</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Segura</surname><given-names>M</given-names></name><name name-style="western"><surname>Gottschalk</surname><given-names>M</given-names></name></person-group><article-title><italic toggle="yes">Streptococcus suis</italic>, an important pig pathogen and emerging zoonotic agent-an update on the worldwide distribution based on serotyping and sequence typing</article-title><source>Emerg Microbes Infect</source><year>2014</year><volume>3</volume><fpage>e45</fpage><pub-id pub-id-type="pmid">26038745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/emi.2014.45</pub-id><pub-id pub-id-type="pmcid">PMC4078792</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Goyette-Desjardins G, Auger JP, Xu J, Segura M, Gottschalk M (2014) <italic toggle="yes">Streptococcus suis</italic>, an important pig pathogen and emerging zoonotic agent-an update on the worldwide distribution based on serotyping and sequence typing. Emerg Microbes Infect 3:e45<pub-id pub-id-type="pmid">26038745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/emi.2014.45</pub-id><pub-id pub-id-type="pmcid">PMC4078792</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Werinder</surname><given-names>A</given-names></name><name name-style="western"><surname>Aspan</surname><given-names>A</given-names></name><name name-style="western"><surname>Backhans</surname><given-names>A</given-names></name><name name-style="western"><surname>Sjolund</surname><given-names>M</given-names></name><name name-style="western"><surname>Guss</surname><given-names>B</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>M</given-names></name></person-group><article-title><italic toggle="yes">Streptococcus suis</italic> in Swedish grower pigs: occurrence, serotypes, and antimicrobial susceptibility</article-title><source>Acta Vet Scand</source><year>2020</year><volume>62</volume><fpage>36</fpage><pub-id pub-id-type="pmid">32580735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13028-020-00533-3</pub-id><pub-id pub-id-type="pmcid">PMC7315512</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Werinder A, Aspan A, Backhans A, Sjolund M, Guss B, Jacobson M (2020) <italic toggle="yes">Streptococcus suis</italic> in Swedish grower pigs: occurrence, serotypes, and antimicrobial susceptibility. Acta Vet Scand 62:36<pub-id pub-id-type="pmid">32580735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13028-020-00533-3</pub-id><pub-id pub-id-type="pmcid">PMC7315512</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arai</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>T</given-names></name><name name-style="western"><surname>Tohya</surname><given-names>M</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>E</given-names></name><name name-style="western"><surname>Ishida-Kuroki</surname><given-names>K</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>F</given-names></name><name name-style="western"><surname>Murase</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>I</given-names></name><name name-style="western"><surname>Sekizaki</surname><given-names>T</given-names></name></person-group><article-title>Assessment of pig saliva as a <italic toggle="yes">Streptococcus suis</italic> reservoir and potential source of infection on farms by use of a novel quantitative polymerase chain reaction assay</article-title><source>Am J Vet Res</source><year>2018</year><volume>79</volume><fpage>941</fpage><lpage>948</lpage><pub-id pub-id-type="pmid">30153059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2460/ajvr.79.9.941</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Arai S, Kim H, Watanabe T, Tohya M, Suzuki E, Ishida-Kuroki K, Maruyama F, Murase K, Nakagawa I, Sekizaki T (2018) Assessment of pig saliva as a <italic toggle="yes">Streptococcus suis</italic> reservoir and potential source of infection on farms by use of a novel quantitative polymerase chain reaction assay. Am J Vet Res 79:941&#8211;948<pub-id pub-id-type="pmid">30153059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2460/ajvr.79.9.941</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neila-Ibanez</surname><given-names>C</given-names></name><name name-style="western"><surname>Casal</surname><given-names>J</given-names></name><name name-style="western"><surname>Hennig-Pauka</surname><given-names>I</given-names></name><name name-style="western"><surname>Stockhofe-Zurwieden</surname><given-names>N</given-names></name><name name-style="western"><surname>Gottschalk</surname><given-names>M</given-names></name><name name-style="western"><surname>Migura-Garcia</surname><given-names>L</given-names></name><name name-style="western"><surname>Pailler-Garcia</surname><given-names>L</given-names></name><name name-style="western"><surname>Napp</surname><given-names>S</given-names></name></person-group><article-title>Stochastic assessment of the economic impact of <italic toggle="yes">Streptococcus suis</italic>-associated disease in German, Dutch and Spanish swine farms</article-title><source>Front Vet Sci</source><year>2021</year><volume>8</volume><fpage>676002</fpage><pub-id pub-id-type="pmid">34490389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fvets.2021.676002</pub-id><pub-id pub-id-type="pmcid">PMC8417327</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Neila-Ibanez C, Casal J, Hennig-Pauka I, Stockhofe-Zurwieden N, Gottschalk M, Migura-Garcia L, Pailler-Garcia L, Napp S (2021) Stochastic assessment of the economic impact of <italic toggle="yes">Streptococcus suis</italic>-associated disease in German, Dutch and Spanish swine farms. Front Vet Sci 8:676002<pub-id pub-id-type="pmid">34490389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fvets.2021.676002</pub-id><pub-id pub-id-type="pmcid">PMC8417327</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wertheim</surname><given-names>HF</given-names></name><name name-style="western"><surname>Nghia</surname><given-names>HD</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>W</given-names></name><name name-style="western"><surname>Schultsz</surname><given-names>C</given-names></name></person-group><article-title><italic toggle="yes">Streptococcus suis</italic>: an emerging human pathogen</article-title><source>Clin Infect Dis</source><year>2009</year><volume>48</volume><fpage>617</fpage><lpage>625</lpage><pub-id pub-id-type="pmid">19191650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/596763</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Wertheim HF, Nghia HD, Taylor W, Schultsz C (2009) <italic toggle="yes">Streptococcus suis</italic>: an emerging human pathogen. Clin Infect Dis 48:617&#8211;625<pub-id pub-id-type="pmid">19191650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/596763</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segura</surname><given-names>M</given-names></name><name name-style="western"><surname>Fittipaldi</surname><given-names>N</given-names></name><name name-style="western"><surname>Calzas</surname><given-names>C</given-names></name><name name-style="western"><surname>Gottschalk</surname><given-names>M</given-names></name></person-group><article-title>Critical <italic toggle="yes">Streptococcus suis</italic> virulence factors: are they all really critical?</article-title><source>Trends Microbiol</source><year>2017</year><volume>25</volume><fpage>585</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">28274524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tim.2017.02.005</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Segura M, Fittipaldi N, Calzas C, Gottschalk M (2017) Critical <italic toggle="yes">Streptococcus suis</italic> virulence factors: are they all really critical? Trends Microbiol 25:585&#8211;599<pub-id pub-id-type="pmid">28274524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tim.2017.02.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Cao</surname><given-names>M</given-names></name><name name-style="western"><surname>Hu</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name></person-group><article-title><italic toggle="yes">Streptococcus suis</italic> infection: an emerging/reemerging challenge of bacterial infectious diseases?</article-title><source>Virulence</source><year>2014</year><volume>5</volume><fpage>477</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">24667807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/viru.28595</pub-id><pub-id pub-id-type="pmcid">PMC4063810</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Feng Y, Zhang H, Wu Z, Wang S, Cao M, Hu D, Wang C (2014) <italic toggle="yes">Streptococcus suis</italic> infection: an emerging/reemerging challenge of bacterial infectious diseases? Virulence 5:477&#8211;497<pub-id pub-id-type="pmid">24667807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/viru.28595</pub-id><pub-id pub-id-type="pmcid">PMC4063810</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Jing</surname><given-names>H</given-names></name><name name-style="western"><surname>Du</surname><given-names>H</given-names></name><name name-style="western"><surname>Segura</surname><given-names>M</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Kan</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Jin</surname><given-names>D</given-names></name><name name-style="western"><surname>Sun</surname><given-names>N</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Dong</surname><given-names>B</given-names></name><name name-style="western"><surname>Ke</surname><given-names>C</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Tian</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gottschalk</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title><italic toggle="yes">Streptococcus suis</italic> sequence type 7 outbreak, Sichuan, China</article-title><source>Emerg Infect Dis</source><year>2006</year><volume>12</volume><fpage>1203</fpage><lpage>1208</lpage><pub-id pub-id-type="pmid">16965698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1208.060232</pub-id><pub-id pub-id-type="pmcid">PMC3291228</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Ye C, Zhu X, Jing H, Du H, Segura M, Zheng H, Kan B, Wang L, Bai X, Zhou Y, Cui Z, Zhang S, Jin D, Sun N, Luo X, Zhang J, Gong Z, Wang X, Wang L, Sun H, Li Z, Sun Q, Liu H, Dong B, Ke C, Yuan H, Wang H, Tian K, Wang Y, Gottschalk M, Xu J (2006) <italic toggle="yes">Streptococcus suis</italic> sequence type 7 outbreak, Sichuan, China. Emerg Infect Dis 12:1203&#8211;1208<pub-id pub-id-type="pmid">16965698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1208.060232</pub-id><pub-id pub-id-type="pmcid">PMC3291228</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottschalk</surname><given-names>M</given-names></name><name name-style="western"><surname>Segura</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title><italic toggle="yes">Streptococcus suis</italic> infections in humans: the Chinese experience and the situation in North America</article-title><source>Anim Health Res Rev</source><year>2007</year><volume>8</volume><fpage>29</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">17692141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1466252307001247</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Gottschalk M, Segura M, Xu J (2007) <italic toggle="yes">Streptococcus suis</italic> infections in humans: the Chinese experience and the situation in North America. Anim Health Res Rev 8:29&#8211;45<pub-id pub-id-type="pmid">17692141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1466252307001247</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segura</surname><given-names>M</given-names></name><name name-style="western"><surname>Aragon</surname><given-names>V</given-names></name><name name-style="western"><surname>Brockmeier</surname><given-names>SL</given-names></name><name name-style="western"><surname>Gebhart</surname><given-names>C</given-names></name><name name-style="western"><surname>Greeff</surname><given-names>A</given-names></name><name name-style="western"><surname>Kerdsin</surname><given-names>A</given-names></name><name name-style="western"><surname>O'Dea</surname><given-names>MA</given-names></name><name name-style="western"><surname>Okura</surname><given-names>M</given-names></name><name name-style="western"><surname>Salery</surname><given-names>M</given-names></name><name name-style="western"><surname>Schultsz</surname><given-names>C</given-names></name><name name-style="western"><surname>Valentin-Weigand</surname><given-names>P</given-names></name><name name-style="western"><surname>Weinert</surname><given-names>LA</given-names></name><name name-style="western"><surname>Wells</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gottschalk</surname><given-names>M</given-names></name></person-group><article-title>Update on <italic toggle="yes">Streptococcus suis</italic> research and prevention in the era of antimicrobial restriction: 4<sup>th</sup> international workshop on <italic toggle="yes">S. suis</italic></article-title><source>Pathogens</source><year>2020</year><volume>9</volume><fpage>379</fpage><pub-id pub-id-type="pmid">32422856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pathogens9050374</pub-id><pub-id pub-id-type="pmcid">PMC7281350</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Segura M, Aragon V, Brockmeier SL, Gebhart C, Greeff A, Kerdsin A, O&#8217;Dea MA, Okura M, Salery M, Schultsz C, Valentin-Weigand P, Weinert LA, Wells JM, Gottschalk M (2020) Update on <italic toggle="yes">Streptococcus suis</italic> research and prevention in the era of antimicrobial restriction: 4<sup>th</sup> international workshop on <italic toggle="yes">S. suis</italic>. Pathogens 9:379<pub-id pub-id-type="pmid">32422856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pathogens9050374</pub-id><pub-id pub-id-type="pmcid">PMC7281350</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottschalk</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Calzas</surname><given-names>C</given-names></name><name name-style="western"><surname>Segura</surname><given-names>M</given-names></name></person-group><article-title><italic toggle="yes">Streptococcus suis</italic>: a new emerging or an old neglected zoonotic pathogen?</article-title><source>Future Microbiol</source><year>2010</year><volume>5</volume><fpage>371</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">20210549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fmb.10.2</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Gottschalk M, Xu J, Calzas C, Segura M (2010) <italic toggle="yes">Streptococcus suis</italic>: a new emerging or an old neglected zoonotic pathogen? Future Microbiol 5:371&#8211;391<pub-id pub-id-type="pmid">20210549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fmb.10.2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uru&#233;n</surname><given-names>C</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>C</given-names></name><name name-style="western"><surname>Fraile</surname><given-names>L</given-names></name><name name-style="western"><surname>Tommassen</surname><given-names>J</given-names></name><name name-style="western"><surname>Arenas</surname><given-names>J</given-names></name></person-group><article-title>How <italic toggle="yes">Streptococcus suis</italic> escapes antibiotic treatments</article-title><source>Vet Res</source><year>2022</year><volume>53</volume><fpage>91</fpage><pub-id pub-id-type="pmid">36371221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13567-022-01111-3</pub-id><pub-id pub-id-type="pmcid">PMC9652813</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Uru&#233;n C, Garc&#237;a C, Fraile L, Tommassen J, Arenas J (2022) How <italic toggle="yes">Streptococcus suis</italic> escapes antibiotic treatments. Vet Res 53:91<pub-id pub-id-type="pmid">36371221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13567-022-01111-3</pub-id><pub-id pub-id-type="pmcid">PMC9652813</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segura</surname><given-names>M</given-names></name></person-group><article-title><italic toggle="yes">Streptococcus suis</italic> vaccines: candidate antigens and progress</article-title><source>Expert Rev Vaccines</source><year>2015</year><volume>14</volume><fpage>1587</fpage><lpage>1608</lpage><pub-id pub-id-type="pmid">26468755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2015.1101349</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Segura M (2015) <italic toggle="yes">Streptococcus suis</italic> vaccines: candidate antigens and progress. Expert Rev Vaccines 14:1587&#8211;1608<pub-id pub-id-type="pmid">26468755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2015.1101349</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Athey</surname><given-names>TB</given-names></name><name name-style="western"><surname>Teatero</surname><given-names>S</given-names></name><name name-style="western"><surname>Lacouture</surname><given-names>S</given-names></name><name name-style="western"><surname>Takamatsu</surname><given-names>D</given-names></name><name name-style="western"><surname>Gottschalk</surname><given-names>M</given-names></name><name name-style="western"><surname>Fittipaldi</surname><given-names>N</given-names></name></person-group><article-title>Determining <italic toggle="yes">Streptococcus suis</italic> serotype from short-read whole-genome sequencing data</article-title><source>BMC Microbiol</source><year>2016</year><volume>16</volume><fpage>162</fpage><pub-id pub-id-type="pmid">27449127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12866-016-0782-8</pub-id><pub-id pub-id-type="pmcid">PMC4957933</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Athey TB, Teatero S, Lacouture S, Takamatsu D, Gottschalk M, Fittipaldi N (2016) Determining <italic toggle="yes">Streptococcus suis</italic> serotype from short-read whole-genome sequencing data. BMC Microbiol 16:162<pub-id pub-id-type="pmid">27449127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12866-016-0782-8</pub-id><pub-id pub-id-type="pmcid">PMC4957933</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roach</surname><given-names>DR</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>DM</given-names></name></person-group><article-title>Antimicrobial bacteriophage-derived proteins and therapeutic applications</article-title><source>Bacteriophage</source><year>2015</year><volume>5</volume><fpage>e1062590</fpage><pub-id pub-id-type="pmid">26442196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21597081.2015.1062590</pub-id><pub-id pub-id-type="pmcid">PMC4590002</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Roach DR, Donovan DM (2015) Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage 5:e1062590<pub-id pub-id-type="pmid">26442196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21597081.2015.1062590</pub-id><pub-id pub-id-type="pmcid">PMC4590002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>DC</given-names></name><name name-style="western"><surname>Schmelcher</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodriguez-Rubio</surname><given-names>L</given-names></name><name name-style="western"><surname>Klumpp</surname><given-names>J</given-names></name><name name-style="western"><surname>Pritchard</surname><given-names>DG</given-names></name><name name-style="western"><surname>Dong</surname><given-names>S</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>DM</given-names></name></person-group><article-title>Endolysins as antimicrobials</article-title><source>Adv Virus Res</source><year>2012</year><volume>83</volume><fpage>299</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">22748813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-394438-2.00007-4</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Nelson DC, Schmelcher M, Rodriguez-Rubio L, Klumpp J, Pritchard DG, Dong S, Donovan DM (2012) Endolysins as antimicrobials. Adv Virus Res 83:299&#8211;365<pub-id pub-id-type="pmid">22748813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-394438-2.00007-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gondil</surname><given-names>VS</given-names></name><name name-style="western"><surname>Harjai</surname><given-names>K</given-names></name><name name-style="western"><surname>Chhibber</surname><given-names>S</given-names></name></person-group><article-title>Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>55</volume><fpage>105844</fpage><pub-id pub-id-type="pmid">31715257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2019.11.001</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Gondil VS, Harjai K, Chhibber S (2020) Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections. Int J Antimicrob Agents 55:105844<pub-id pub-id-type="pmid">31715257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2019.11.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelkader</surname><given-names>K</given-names></name><name name-style="western"><surname>Gerstmans</surname><given-names>H</given-names></name><name name-style="western"><surname>Saafan</surname><given-names>A</given-names></name><name name-style="western"><surname>Dishisha</surname><given-names>T</given-names></name><name name-style="western"><surname>Briers</surname><given-names>Y</given-names></name></person-group><article-title>The preclinical and clinical progress of bacteriophages and their lytic enzymes: the parts are easier than the whole</article-title><source>Viruses</source><year>2019</year><volume>11</volume><fpage>96</fpage><pub-id pub-id-type="pmid">30678377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v11020096</pub-id><pub-id pub-id-type="pmcid">PMC6409994</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Abdelkader K, Gerstmans H, Saafan A, Dishisha T, Briers Y (2019) The preclinical and clinical progress of bacteriophages and their lytic enzymes: the parts are easier than the whole. Viruses 11:96<pub-id pub-id-type="pmid">30678377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v11020096</pub-id><pub-id pub-id-type="pmcid">PMC6409994</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yan</surname><given-names>YX</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name></person-group><article-title>A novel prophage lysin Ply5218 with extended lytic activity and stability against <italic toggle="yes">Streptococcus suis</italic> infection</article-title><source>FEMS Microbiol Lett</source><year>2016</year><volume>363</volume><fpage>fnw186</fpage><pub-id pub-id-type="pmid">27481700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/femsle/fnw186</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Zhang H, Zhang C, Wang H, Yan YX, Sun J (2016) A novel prophage lysin Ply5218 with extended lytic activity and stability against <italic toggle="yes">Streptococcus suis</italic> infection. FEMS Microbiol Lett 363:fnw186<pub-id pub-id-type="pmid">27481700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/femsle/fnw186</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name></person-group><article-title>Lysogenic <italic toggle="yes">Streptococcus suis</italic> isolate SS2-4 containing prophage SMP showed increased mortality in zebra fish compared to the wild-type isolate</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e54227</fpage><pub-id pub-id-type="pmid">23326601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0054227</pub-id><pub-id pub-id-type="pmcid">PMC3542266</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Tang F, Zhang W, Lu C (2013) Lysogenic <italic toggle="yes">Streptococcus suis</italic> isolate SS2-4 containing prophage SMP showed increased mortality in zebra fish compared to the wild-type isolate. PLoS One 8:e54227<pub-id pub-id-type="pmid">23326601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0054227</pub-id><pub-id pub-id-type="pmcid">PMC3542266</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osei</surname><given-names>EK</given-names></name><name name-style="western"><surname>O'Hea</surname><given-names>R</given-names></name><name name-style="western"><surname>Cambillau</surname><given-names>C</given-names></name><name name-style="western"><surname>Athalye</surname><given-names>A</given-names></name><name name-style="western"><surname>Hille</surname><given-names>F</given-names></name><name name-style="western"><surname>Franz</surname><given-names>C</given-names></name><name name-style="western"><surname>O'Doherty</surname><given-names>A</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>M</given-names></name><name name-style="western"><surname>Murray</surname><given-names>GGR</given-names></name><name name-style="western"><surname>Weinert</surname><given-names>LA</given-names></name><name name-style="western"><surname>Manzanilla</surname><given-names>EG</given-names></name><name name-style="western"><surname>Mahony</surname><given-names>J</given-names></name><name name-style="western"><surname>Kenny</surname><given-names>JG</given-names></name></person-group><article-title>Isolation of phages infecting the zoonotic pathogen <italic toggle="yes">Streptococcus suis</italic> reveals novel structural and genomic characteristics</article-title><source>Microbiol Res</source><year>2025</year><volume>296</volume><fpage>128147</fpage><pub-id pub-id-type="pmid">40132484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micres.2025.128147</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Osei EK, O&#8217;Hea R, Cambillau C, Athalye A, Hille F, Franz C, O&#8217;Doherty A, Wilson M, Murray GGR, Weinert LA, Manzanilla EG, Mahony J, Kenny JG (2025) Isolation of phages infecting the zoonotic pathogen <italic toggle="yes">Streptococcus suis</italic> reveals novel structural and genomic characteristics. Microbiol Res 296:128147<pub-id pub-id-type="pmid">40132484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micres.2025.128147</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liang</surname><given-names>S</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Xie</surname><given-names>F</given-names></name></person-group><article-title>Bacteriophage endolysin Ply113 as a potent antibacterial agent against polymicrobial biofilms formed by <italic toggle="yes">enterococci</italic> and <italic toggle="yes">Staphylococcus aureus</italic></article-title><source>Front Microbiol</source><year>2023</year><volume>14</volume><fpage>1304932</fpage><pub-id pub-id-type="pmid">38152375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2023.1304932</pub-id><pub-id pub-id-type="pmcid">PMC10751913</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Wang J, Liang S, Lu X, Xu Q, Zhu Y, Yu S, Zhang W, Liu S, Xie F (2023) Bacteriophage endolysin Ply113 as a potent antibacterial agent against polymicrobial biofilms formed by <italic toggle="yes">enterococci</italic> and <italic toggle="yes">Staphylococcus aureus</italic>. Front Microbiol 14:1304932<pub-id pub-id-type="pmid">38152375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2023.1304932</pub-id><pub-id pub-id-type="pmcid">PMC10751913</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Gottschalk</surname><given-names>M</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X</given-names></name><name name-style="western"><surname>Lan</surname><given-names>R</given-names></name><name name-style="western"><surname>Ji</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>Development of multiplex PCR assays for the identification of the 33 serotypes of <italic toggle="yes">Streptococcus suis</italic></article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e72070</fpage><pub-id pub-id-type="pmid">23951285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0072070</pub-id><pub-id pub-id-type="pmcid">PMC3739753</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Liu Z, Zheng H, Gottschalk M, Bai X, Lan R, Ji S, Liu H, Xu J (2013) Development of multiplex PCR assays for the identification of the 33 serotypes of <italic toggle="yes">Streptococcus suis</italic>. PLoS One 8:e72070<pub-id pub-id-type="pmid">23951285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0072070</pub-id><pub-id pub-id-type="pmcid">PMC3739753</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>S</given-names></name><name name-style="western"><surname>Xie</surname><given-names>F</given-names></name></person-group><article-title>Bactericidal synergism between phage endolysin Ply2660 and cathelicidin LL-37 against vancomycin-resistant <italic toggle="yes">Enterococcus faecalis</italic> biofilms</article-title><source>NPJ Biofilms Microbiomes</source><year>2023</year><volume>9</volume><fpage>16</fpage><pub-id pub-id-type="pmid">37024490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41522-023-00385-5</pub-id><pub-id pub-id-type="pmcid">PMC10078070</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Zhang H, Zhang X, Liang S, Wang J, Zhu Y, Zhang W, Liu S, Schwarz S, Xie F (2023) Bactericidal synergism between phage endolysin Ply2660 and cathelicidin LL-37 against vancomycin-resistant <italic toggle="yes">Enterococcus faecalis</italic> biofilms. NPJ Biofilms Microbiomes 9:16<pub-id pub-id-type="pmid">37024490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41522-023-00385-5</pub-id><pub-id pub-id-type="pmcid">PMC10078070</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>S</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yi</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Methyl anthranilate deteriorates biofilm structure of <italic toggle="yes">Streptococcus suis</italic> and antagonizes the capsular polysaccharide defence effect</article-title><source>Int J Antimicrob Agents</source><year>2023</year><volume>62</volume><fpage>106996</fpage><pub-id pub-id-type="pmid">37788717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2023.106996</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Gao S, Shen Y, Yuan S, Quan Y, Li X, Wang Y, Yi L, Wang Y (2023) Methyl anthranilate deteriorates biofilm structure of <italic toggle="yes">Streptococcus suis</italic> and antagonizes the capsular polysaccharide defence effect. Int J Antimicrob Agents 62:106996<pub-id pub-id-type="pmid">37788717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2023.106996</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Breij</surname><given-names>A</given-names></name><name name-style="western"><surname>Riool</surname><given-names>M</given-names></name><name name-style="western"><surname>Cordfunke</surname><given-names>RA</given-names></name><name name-style="western"><surname>Malanovic</surname><given-names>N</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>L</given-names></name><name name-style="western"><surname>Koning</surname><given-names>RI</given-names></name><name name-style="western"><surname>Ravensbergen</surname><given-names>E</given-names></name><name name-style="western"><surname>Franken</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Heijde</surname><given-names>T</given-names></name><name name-style="western"><surname>Boekema</surname><given-names>BK</given-names></name><name name-style="western"><surname>Kwakman</surname><given-names>PHS</given-names></name><name name-style="western"><surname>Kamp</surname><given-names>N</given-names></name><name name-style="western"><surname>El Ghalbzouri</surname><given-names>A</given-names></name><name name-style="western"><surname>Lohner</surname><given-names>K</given-names></name><name name-style="western"><surname>Zaat</surname><given-names>SAJ</given-names></name><name name-style="western"><surname>Drijfhout</surname><given-names>JW</given-names></name><name name-style="western"><surname>Nibbering</surname><given-names>PH</given-names></name></person-group><article-title>The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms</article-title><source>Sci Transl Med</source><year>2018</year><volume>10</volume><fpage>eaan4044</fpage><pub-id pub-id-type="pmid">29321257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aan4044</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">de Breij A, Riool M, Cordfunke RA, Malanovic N, de Boer L, Koning RI, Ravensbergen E, Franken M, van der Heijde T, Boekema BK, Kwakman PHS, Kamp N, El Ghalbzouri A, Lohner K, Zaat SAJ, Drijfhout JW, Nibbering PH (2018) The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms. Sci Transl Med 10:eaan4044<pub-id pub-id-type="pmid">29321257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.aan4044</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>G</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Han</surname><given-names>P</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H</given-names></name></person-group><article-title><italic toggle="yes">Staphylococcus aureus</italic> SaeRS impairs macrophage immune functions through bacterial clumps formation in the early stage of infection</article-title><source>NPJ Biofilms Microbiomes</source><year>2024</year><volume>10</volume><fpage>102</fpage><pub-id pub-id-type="pmid">39370453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41522-024-00576-8</pub-id><pub-id pub-id-type="pmcid">PMC11456606</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Li M, Wang B, Chen J, Jiang L, Zhou Y, Guo G, Jiang F, Hu Y, Wang C, Yang Y, Tang J, Han P, Yu J, Shen H (2024) <italic toggle="yes">Staphylococcus aureus</italic> SaeRS impairs macrophage immune functions through bacterial clumps formation in the early stage of infection. NPJ Biofilms Microbiomes 10:102<pub-id pub-id-type="pmid">39370453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41522-024-00576-8</pub-id><pub-id pub-id-type="pmcid">PMC11456606</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heydorn</surname><given-names>A</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>AT</given-names></name><name name-style="western"><surname>Hentzer</surname><given-names>M</given-names></name><name name-style="western"><surname>Sternberg</surname><given-names>C</given-names></name><name name-style="western"><surname>Givskov</surname><given-names>M</given-names></name><name name-style="western"><surname>Ersboll</surname><given-names>BK</given-names></name><name name-style="western"><surname>Molin</surname><given-names>S</given-names></name></person-group><article-title>Quantification of biofilm structures by the novel computer program COMSTAT</article-title><source>Microbiology</source><year>2000</year><volume>146</volume><fpage>2395</fpage><lpage>2407</lpage><pub-id pub-id-type="pmid">11021916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/00221287-146-10-2395</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Heydorn A, Nielsen AT, Hentzer M, Sternberg C, Givskov M, Ersboll BK, Molin S (2000) Quantification of biofilm structures by the novel computer program COMSTAT. Microbiology 146:2395&#8211;2407<pub-id pub-id-type="pmid">11021916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/00221287-146-10-2395</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>CA</given-names></name><name name-style="western"><surname>Rasband</surname><given-names>WS</given-names></name><name name-style="western"><surname>Eliceiri</surname><given-names>KW</given-names></name></person-group><article-title>NIH image to ImageJ: 25 years of image analysis</article-title><source>Nat Methods</source><year>2012</year><volume>9</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">22930834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.2089</pub-id><pub-id pub-id-type="pmcid">PMC5554542</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Schneider CA, Rasband WS, Eliceiri KW (2012) NIH image to ImageJ: 25 years of image analysis. Nat Methods 9:671&#8211;675<pub-id pub-id-type="pmid">22930834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.2089</pub-id><pub-id pub-id-type="pmcid">PMC5554542</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bleuze</surname><given-names>M</given-names></name><name name-style="western"><surname>Lehoux</surname><given-names>M</given-names></name><name name-style="western"><surname>Auger</surname><given-names>JP</given-names></name><name name-style="western"><surname>Gottschalk</surname><given-names>M</given-names></name><name name-style="western"><surname>Segura</surname><given-names>M</given-names></name></person-group><article-title>The granulocyte colony-stimulating factor produced during <italic toggle="yes">Streptococcus suis</italic> infection controls neutrophil recruitment in the blood without affecting bacterial clearance</article-title><source>Front Immunol</source><year>2024</year><volume>15</volume><fpage>1403789</fpage><pub-id pub-id-type="pmid">39156897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1403789</pub-id><pub-id pub-id-type="pmcid">PMC11327821</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Bleuze M, Lehoux M, Auger JP, Gottschalk M, Segura M (2024) The granulocyte colony-stimulating factor produced during <italic toggle="yes">Streptococcus suis</italic> infection controls neutrophil recruitment in the blood without affecting bacterial clearance. Front Immunol 15:1403789<pub-id pub-id-type="pmid">39156897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2024.1403789</pub-id><pub-id pub-id-type="pmcid">PMC11327821</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutkiewicz</surname><given-names>J</given-names></name><name name-style="western"><surname>Sroka</surname><given-names>J</given-names></name><name name-style="western"><surname>Zajac</surname><given-names>V</given-names></name><name name-style="western"><surname>Wasinski</surname><given-names>B</given-names></name><name name-style="western"><surname>Cisak</surname><given-names>E</given-names></name><name name-style="western"><surname>Sawczyn</surname><given-names>A</given-names></name><name name-style="western"><surname>Kloc</surname><given-names>A</given-names></name><name name-style="western"><surname>Wojcik-Fatla</surname><given-names>A</given-names></name></person-group><article-title><italic toggle="yes">Streptococcus suis</italic>: a re-emerging pathogen associated with occupational exposure to pigs or pork products. Part I - epidemiology</article-title><source>Ann Agric Environ Med</source><year>2017</year><volume>24</volume><fpage>683</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">29284248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26444/aaem/79813</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Dutkiewicz J, Sroka J, Zajac V, Wasinski B, Cisak E, Sawczyn A, Kloc A, Wojcik-Fatla A (2017) <italic toggle="yes">Streptococcus suis</italic>: a re-emerging pathogen associated with occupational exposure to pigs or pork products. Part I - epidemiology. Ann Agric Environ Med 24:683&#8211;695<pub-id pub-id-type="pmid">29284248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26444/aaem/79813</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name><name name-style="western"><surname>Si</surname><given-names>X</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name></person-group><article-title>Current prevalence and therapeutic strategies for porcine <italic toggle="yes">Streptococcus suis</italic> in China</article-title><source>Appl Environ Microbiol</source><year>2025</year><volume>91</volume><fpage>e0216024</fpage><pub-id pub-id-type="pmid">39998255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aem.02160-24</pub-id><pub-id pub-id-type="pmcid">PMC11921377</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Lv R, Zhang W, Sun Z, Si X, Dong H, Liu X (2025) Current prevalence and therapeutic strategies for porcine <italic toggle="yes">Streptococcus suis</italic> in China. Appl Environ Microbiol 91:e0216024<pub-id pub-id-type="pmid">39998255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aem.02160-24</pub-id><pub-id pub-id-type="pmcid">PMC11921377</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dechene-Tempier</surname><given-names>M</given-names></name><name name-style="western"><surname>Marois-Crehan</surname><given-names>C</given-names></name><name name-style="western"><surname>Libante</surname><given-names>V</given-names></name><name name-style="western"><surname>Jouy</surname><given-names>E</given-names></name><name name-style="western"><surname>Leblond-Bourget</surname><given-names>N</given-names></name><name name-style="western"><surname>Payot</surname><given-names>S</given-names></name></person-group><article-title>Update on the mechanisms of antibiotic resistance and the mobile resistome in the emerging zoonotic pathogen <italic toggle="yes">Streptococcus suis</italic></article-title><source>Microorganisms</source><year>2021</year><volume>9</volume><fpage>1765</fpage><pub-id pub-id-type="pmid">34442843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/microorganisms9081765</pub-id><pub-id pub-id-type="pmcid">PMC8401462</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Dechene-Tempier M, Marois-Crehan C, Libante V, Jouy E, Leblond-Bourget N, Payot S (2021) Update on the mechanisms of antibiotic resistance and the mobile resistome in the emerging zoonotic pathogen <italic toggle="yes">Streptococcus suis</italic>. Microorganisms 9:1765<pub-id pub-id-type="pmid">34442843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/microorganisms9081765</pub-id><pub-id pub-id-type="pmcid">PMC8401462</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>P</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name><name name-style="western"><surname>Kahaer</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Xia</surname><given-names>F</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>Lei</surname><given-names>L</given-names></name><name name-style="western"><surname>Han</surname><given-names>W</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name></person-group><article-title>Characterization of <italic toggle="yes">Enterococcus faecium</italic> bacteriophage IME-EFm5 and its endolysin LysEFm5</article-title><source>Virology</source><year>2016</year><volume>492</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">26896930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2016.02.006</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Gong P, Cheng M, Li X, Jiang H, Yu C, Kahaer N, Li J, Zhang L, Xia F, Hu L, Sun C, Feng X, Lei L, Han W, Gu J (2016) Characterization of <italic toggle="yes">Enterococcus faecium</italic> bacteriophage IME-EFm5 and its endolysin LysEFm5. Virology 492:11&#8211;20<pub-id pub-id-type="pmid">26896930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2016.02.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name><name name-style="western"><surname>Gong</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Cai</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lei</surname><given-names>L</given-names></name><name name-style="western"><surname>Han</surname><given-names>W</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name></person-group><article-title>Endolysin LysEF-P10 shows potential as an alternative treatment strategy for multidrug-resistant <italic toggle="yes">Enterococcus faecalis</italic> infections</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>10164</fpage><pub-id pub-id-type="pmid">28860505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-10755-7</pub-id><pub-id pub-id-type="pmcid">PMC5579260</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Cheng M, Zhang Y, Li X, Liang J, Hu L, Gong P, Zhang L, Cai R, Zhang H, Ge J, Ji Y, Guo Z, Feng X, Sun C, Yang Y, Lei L, Han W, Gu J (2017) Endolysin LysEF-P10 shows potential as an alternative treatment strategy for multidrug-resistant <italic toggle="yes">Enterococcus faecalis</italic> infections. Sci Rep 7:10164<pub-id pub-id-type="pmid">28860505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-10755-7</pub-id><pub-id pub-id-type="pmcid">PMC5579260</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uchiyama</surname><given-names>J</given-names></name><name name-style="western"><surname>Takemura</surname><given-names>I</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>I</given-names></name><name name-style="western"><surname>Matsuzaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>M</given-names></name><name name-style="western"><surname>Ujihara</surname><given-names>T</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>M</given-names></name><name name-style="western"><surname>Imajoh</surname><given-names>M</given-names></name><name name-style="western"><surname>Sugai</surname><given-names>M</given-names></name><name name-style="western"><surname>Daibata</surname><given-names>M</given-names></name></person-group><article-title>Characterization of lytic enzyme open reading frame 9 (ORF9) derived from <italic toggle="yes">Enterococcus faecalis</italic> bacteriophage phiEF24C</article-title><source>Appl Environ Microbiol</source><year>2011</year><volume>77</volume><fpage>580</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">21097580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AEM.01540-10</pub-id><pub-id pub-id-type="pmcid">PMC3020548</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Uchiyama J, Takemura I, Hayashi I, Matsuzaki S, Satoh M, Ujihara T, Murakami M, Imajoh M, Sugai M, Daibata M (2011) Characterization of lytic enzyme open reading frame 9 (ORF9) derived from <italic toggle="yes">Enterococcus faecalis</italic> bacteriophage phiEF24C. Appl Environ Microbiol 77:580&#8211;585<pub-id pub-id-type="pmid">21097580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AEM.01540-10</pub-id><pub-id pub-id-type="pmcid">PMC3020548</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yi</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Rethinking the control of <italic toggle="yes">Streptococcus suis</italic> infection: biofilm formation</article-title><source>Vet Microbiol</source><year>2024</year><volume>290</volume><fpage>110005</fpage><pub-id pub-id-type="pmid">38280304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vetmic.2024.110005</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Wang H, Fan Q, Wang Y, Yi L, Wang Y (2024) Rethinking the control of <italic toggle="yes">Streptococcus suis</italic> infection: biofilm formation. Vet Microbiol 290:110005<pub-id pub-id-type="pmid">38280304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vetmic.2024.110005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>F</given-names></name><name name-style="western"><surname>Yi</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H</given-names></name></person-group><article-title><italic toggle="yes">Streptococcus suis</italic> serotype 2 biofilms inhibit the formation of neutrophil extracellular traps</article-title><source>Front Cell Infect Microbiol</source><year>2017</year><volume>7</volume><fpage>86</fpage><pub-id pub-id-type="pmid">28373968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2017.00086</pub-id><pub-id pub-id-type="pmcid">PMC5357632</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Ma F, Yi L, Yu N, Wang G, Ma Z, Lin H, Fan H (2017) <italic toggle="yes">Streptococcus suis</italic> serotype 2 biofilms inhibit the formation of neutrophil extracellular traps. Front Cell Infect Microbiol 7:86<pub-id pub-id-type="pmid">28373968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2017.00086</pub-id><pub-id pub-id-type="pmcid">PMC5357632</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>L</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Establishment of <italic toggle="yes">Streptococcus suis</italic> biofilm infection model <italic toggle="yes">in vivo</italic> and comparative analysis of gene expression profiles between <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> biofilms</article-title><source>Microbiol Spectr</source><year>2023</year><volume>11</volume><fpage>e0268622</fpage><pub-id pub-id-type="pmid">36507687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/spectrum.02686-22</pub-id><pub-id pub-id-type="pmcid">PMC9927446</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Yi L, Fan Q, Wang H, Fan H, Zuo J, Wang Y, Wang Y (2023) Establishment of <italic toggle="yes">Streptococcus suis</italic> biofilm infection model <italic toggle="yes">in vivo</italic> and comparative analysis of gene expression profiles between <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> biofilms. Microbiol Spectr 11:e0268622<pub-id pub-id-type="pmid">36507687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/spectrum.02686-22</pub-id><pub-id pub-id-type="pmcid">PMC9927446</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dawei</surname><given-names>G</given-names></name><name name-style="western"><surname>Liping</surname><given-names>W</given-names></name><name name-style="western"><surname>Chengping</surname><given-names>L</given-names></name></person-group><article-title>In vitro biofilm forming potential of <italic toggle="yes">Streptococcus suis</italic> isolated from human and swine in China</article-title><source>Braz J Microbiol</source><year>2012</year><volume>43</volume><fpage>993</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">24031918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/S1517-838220120003000021</pub-id><pub-id pub-id-type="pmcid">PMC3768863</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Dawei G, Liping W, Chengping L (2012) In vitro biofilm forming potential of <italic toggle="yes">Streptococcus suis</italic> isolated from human and swine in China. Braz J Microbiol 43:993&#8211;1004<pub-id pub-id-type="pmid">24031918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/S1517-838220120003000021</pub-id><pub-id pub-id-type="pmcid">PMC3768863</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yao</surname><given-names>H</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>The effectiveness of extended binding affinity of prophage lysin PlyARI against <italic toggle="yes">Streptococcus suis</italic> infection</article-title><source>Arch Microbiol</source><year>2021</year><volume>203</volume><fpage>5163</fpage><lpage>5172</lpage><pub-id pub-id-type="pmid">34338822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00203-021-02438-9</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Xiao Y, Chen R, Li M, Qi Z, Yu Y, Pan Z, Yao H, Feng Z, Zhang W (2021) The effectiveness of extended binding affinity of prophage lysin PlyARI against <italic toggle="yes">Streptococcus suis</italic> infection. Arch Microbiol 203:5163&#8211;5172<pub-id pub-id-type="pmid">34338822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00203-021-02438-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>F</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C</given-names></name><name name-style="western"><surname>Lei</surname><given-names>L</given-names></name><name name-style="western"><surname>Han</surname><given-names>W</given-names></name><name name-style="western"><surname>Du</surname><given-names>XD</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name></person-group><article-title>A novel lysin Ply1228 provides efficient protection against <italic toggle="yes">Streptococcus suis</italic> type 2 infection in a murine bacteremia model</article-title><source>Vet Microbiol</source><year>2022</year><volume>268</volume><fpage>109425</fpage><pub-id pub-id-type="pmid">35397385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vetmic.2022.109425</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Wang Z, Liu X, Shi Z, Zhao R, Ji Y, Tang F, Guan Y, Feng X, Sun C, Lei L, Han W, Du XD, Gu J (2022) A novel lysin Ply1228 provides efficient protection against <italic toggle="yes">Streptococcus suis</italic> type 2 infection in a murine bacteremia model. Vet Microbiol 268:109425<pub-id pub-id-type="pmid">35397385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vetmic.2022.109425</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilmer</surname><given-names>DB</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>JE</given-names></name><name name-style="western"><surname>Thandar</surname><given-names>M</given-names></name><name name-style="western"><surname>Euler</surname><given-names>CW</given-names></name><name name-style="western"><surname>Fischetti</surname><given-names>VA</given-names></name></person-group><article-title>The phage lysin PlySs2 decolonizes <italic toggle="yes">Streptococcus suis</italic> from murine intranasal mucosa</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><fpage>e0169180</fpage><pub-id pub-id-type="pmid">28046082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0169180</pub-id><pub-id pub-id-type="pmcid">PMC5207509</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Gilmer DB, Schmitz JE, Thandar M, Euler CW, Fischetti VA (2017) The phage lysin PlySs2 decolonizes <italic toggle="yes">Streptococcus suis</italic> from murine intranasal mucosa. PLoS One 12:e0169180<pub-id pub-id-type="pmid">28046082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0169180</pub-id><pub-id pub-id-type="pmcid">PMC5207509</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><name name-style="western"><surname>Dai</surname><given-names>J</given-names></name></person-group><article-title>Prophage lysin Ply30 protects mice from <italic toggle="yes">Streptococcus suis</italic> and <italic toggle="yes">Streptococcus equi</italic> subsp. <italic toggle="yes">zooepidemicus</italic> infections</article-title><source>Appl Environ Microbiol</source><year>2015</year><volume>81</volume><fpage>7377</fpage><lpage>7384</lpage><pub-id pub-id-type="pmid">26253669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AEM.02300-15</pub-id><pub-id pub-id-type="pmcid">PMC4592866</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Tang F, Li D, Wang H, Ma Z, Lu C, Dai J (2015) Prophage lysin Ply30 protects mice from <italic toggle="yes">Streptococcus suis</italic> and <italic toggle="yes">Streptococcus equi</italic> subsp. <italic toggle="yes">zooepidemicus</italic> infections. Appl Environ Microbiol 81:7377&#8211;7384<pub-id pub-id-type="pmid">26253669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AEM.02300-15</pub-id><pub-id pub-id-type="pmcid">PMC4592866</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name></person-group><article-title>A novel endolysin disrupts <italic toggle="yes">Streptococcus suis</italic> with high efficiency</article-title><source>FEMS Microbiol Lett</source><year>2015</year><volume>362</volume><fpage>fnv205</fpage><pub-id pub-id-type="pmid">26534896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/femsle/fnv205</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Ji W, Huang Q, Sun L, Wang H, Yan Y, Sun J (2015) A novel endolysin disrupts <italic toggle="yes">Streptococcus suis</italic> with high efficiency. FEMS Microbiol Lett 362:fnv205<pub-id pub-id-type="pmid">26534896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/femsle/fnv205</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ji</surname><given-names>W</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name></person-group><article-title>Application of a bacteriophage lysin to disrupt biofilms formed by the animal pathogen <italic toggle="yes">Streptococcus suis</italic></article-title><source>Appl Environ Microbiol</source><year>2011</year><volume>77</volume><fpage>8272</fpage><lpage>8279</lpage><pub-id pub-id-type="pmid">21984241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AEM.05151-11</pub-id><pub-id pub-id-type="pmcid">PMC3233067</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Meng X, Shi Y, Ji W, Meng X, Zhang J, Wang H, Lu C, Sun J, Yan Y (2011) Application of a bacteriophage lysin to disrupt biofilms formed by the animal pathogen <italic toggle="yes">Streptococcus suis</italic>. Appl Environ Microbiol 77:8272&#8211;8279<pub-id pub-id-type="pmid">21984241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AEM.05151-11</pub-id><pub-id pub-id-type="pmcid">PMC3233067</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xi</surname><given-names>H</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X</given-names></name><name name-style="western"><surname>Han</surname><given-names>W</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y</given-names></name></person-group><article-title><italic toggle="yes">Aerococcus viridans</italic> phage lysin AVPL had lytic activity against <italic toggle="yes">Streptococcus suis</italic> in a mouse bacteremia model</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><fpage>16670</fpage><pub-id pub-id-type="pmid">38068990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms242316670</pub-id><pub-id pub-id-type="pmcid">PMC10706753</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Xi H, Fu Y, Chen C, Feng X, Han W, Gu J, Ji Y (2023) <italic toggle="yes">Aerococcus viridans</italic> phage lysin AVPL had lytic activity against <italic toggle="yes">Streptococcus suis</italic> in a mouse bacteremia model. Int J Mol Sci 24:16670<pub-id pub-id-type="pmid">38068990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms242316670</pub-id><pub-id pub-id-type="pmcid">PMC10706753</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelrahman</surname><given-names>F</given-names></name><name name-style="western"><surname>Easwaran</surname><given-names>M</given-names></name><name name-style="western"><surname>Daramola</surname><given-names>OI</given-names></name><name name-style="western"><surname>Ragab</surname><given-names>S</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>S</given-names></name><name name-style="western"><surname>Oduselu</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Khan</surname><given-names>FM</given-names></name><name name-style="western"><surname>Ayobami</surname><given-names>A</given-names></name><name name-style="western"><surname>Adnan</surname><given-names>F</given-names></name><name name-style="western"><surname>Torrents</surname><given-names>E</given-names></name><name name-style="western"><surname>Sanmukh</surname><given-names>S</given-names></name><name name-style="western"><surname>El-Shibiny</surname><given-names>A</given-names></name></person-group><article-title>Phage-encoded endolysins</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><fpage>124</fpage><pub-id pub-id-type="pmid">33525684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antibiotics10020124</pub-id><pub-id pub-id-type="pmcid">PMC7912344</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Abdelrahman F, Easwaran M, Daramola OI, Ragab S, Lynch S, Oduselu TJ, Khan FM, Ayobami A, Adnan F, Torrents E, Sanmukh S, El-Shibiny A (2021) Phage-encoded endolysins. Antibiotics 10:124<pub-id pub-id-type="pmid">33525684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antibiotics10020124</pub-id><pub-id pub-id-type="pmcid">PMC7912344</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jun</surname><given-names>SY</given-names></name><name name-style="western"><surname>Jung</surname><given-names>GM</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Choi</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Koh</surname><given-names>WS</given-names></name><name name-style="western"><surname>Moon</surname><given-names>KS</given-names></name><name name-style="western"><surname>Kang</surname><given-names>SH</given-names></name></person-group><article-title>Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><fpage>2084</fpage><lpage>2088</lpage><pub-id pub-id-type="pmid">24449776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.02232-13</pub-id><pub-id pub-id-type="pmcid">PMC4023757</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Jun SY, Jung GM, Yoon SJ, Choi YJ, Koh WS, Moon KS, Kang SH (2014) Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob Agents Chemother 58:2084&#8211;2088<pub-id pub-id-type="pmid">24449776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.02232-13</pub-id><pub-id pub-id-type="pmcid">PMC4023757</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jun</surname><given-names>SY</given-names></name><name name-style="western"><surname>Jung</surname><given-names>GM</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Youm</surname><given-names>SY</given-names></name><name name-style="western"><surname>Han</surname><given-names>HY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kang</surname><given-names>SH</given-names></name></person-group><article-title>Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period</article-title><source>Clin Exp Pharmacol Physiol</source><year>2016</year><volume>43</volume><fpage>1013</fpage><lpage>1016</lpage><pub-id pub-id-type="pmid">27341401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1440-1681.12613</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Jun SY, Jung GM, Yoon SJ, Youm SY, Han HY, Lee JH, Kang SH (2016) Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period. Clin Exp Pharmacol Physiol 43:1013&#8211;1016<pub-id pub-id-type="pmid">27341401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1440-1681.12613</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jun</surname><given-names>SY</given-names></name><name name-style="western"><surname>Jang</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>S</given-names></name><name name-style="western"><surname>Jang</surname><given-names>K</given-names></name><name name-style="western"><surname>Yu</surname><given-names>KS</given-names></name><name name-style="western"><surname>Cho</surname><given-names>JY</given-names></name><name name-style="western"><surname>Seong</surname><given-names>MW</given-names></name><name name-style="western"><surname>Jung</surname><given-names>GM</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kang</surname><given-names>SH</given-names></name></person-group><article-title>Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers</article-title><source>Antimicrob Agents Chemother</source><year>2017</year><volume>61</volume><fpage>e02629&#8211;16</fpage><pub-id pub-id-type="pmid">28348152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.02629-16</pub-id><pub-id pub-id-type="pmcid">PMC5444177</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Jun SY, Jang IJ, Yoon S, Jang K, Yu KS, Cho JY, Seong MW, Jung GM, Yoon SJ, Kang SH (2017) Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a single intravenous administration among healthy volunteers. Antimicrob Agents Chemother 61:e02629&#8211;16<pub-id pub-id-type="pmid">28348152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.02629-16</pub-id><pub-id pub-id-type="pmcid">PMC5444177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>E</given-names></name><name name-style="western"><surname>Draper</surname><given-names>LA</given-names></name><name name-style="western"><surname>Ross</surname><given-names>RP</given-names></name><name name-style="western"><surname>Hill</surname><given-names>C</given-names></name></person-group><article-title>The advantages and challenges of using endolysins in a clinical setting</article-title><source>Viruses</source><year>2021</year><volume>13</volume><fpage>680</fpage><pub-id pub-id-type="pmid">33920965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v13040680</pub-id><pub-id pub-id-type="pmcid">PMC8071259</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Murray E, Draper LA, Ross RP, Hill C (2021) The advantages and challenges of using endolysins in a clinical setting. Viruses 13:680<pub-id pub-id-type="pmid">33920965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v13040680</pub-id><pub-id pub-id-type="pmcid">PMC8071259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>FM</given-names></name><name name-style="western"><surname>Rasheed</surname><given-names>F</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name></person-group><article-title>Endolysins: a new antimicrobial agent against antimicrobial resistance. Strategies and opportunities in overcoming the challenges of endolysins against Gram-negative bacteria</article-title><source>Front Pharmacol</source><year>2024</year><volume>15</volume><fpage>1385261</fpage><pub-id pub-id-type="pmid">38831886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2024.1385261</pub-id><pub-id pub-id-type="pmcid">PMC11144922</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Khan FM, Rasheed F, Yang Y, Liu B, Zhang R (2024) Endolysins: a new antimicrobial agent against antimicrobial resistance. Strategies and opportunities in overcoming the challenges of endolysins against Gram-negative bacteria. Front Pharmacol 15:1385261<pub-id pub-id-type="pmid">38831886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2024.1385261</pub-id><pub-id pub-id-type="pmcid">PMC11144922</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Entenza</surname><given-names>JM</given-names></name><name name-style="western"><surname>Loeffler</surname><given-names>JM</given-names></name><name name-style="western"><surname>Grandgirard</surname><given-names>D</given-names></name><name name-style="western"><surname>Fischetti</surname><given-names>VA</given-names></name><name name-style="western"><surname>Moreillon</surname><given-names>P</given-names></name></person-group><article-title>Therapeutic effects of bacteriophage Cpl-1 lysin against <italic toggle="yes">Streptococcus pneumoniae</italic> endocarditis in rats</article-title><source>Antimicrob Agents Chemother</source><year>2005</year><volume>49</volume><fpage>4789</fpage><lpage>4792</lpage><pub-id pub-id-type="pmid">16251333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.49.11.4789-4792.2005</pub-id><pub-id pub-id-type="pmcid">PMC1280127</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P (2005) Therapeutic effects of bacteriophage Cpl-1 lysin against <italic toggle="yes">Streptococcus pneumoniae</italic> endocarditis in rats. Antimicrob Agents Chemother 49:4789&#8211;4792<pub-id pub-id-type="pmid">16251333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.49.11.4789-4792.2005</pub-id><pub-id pub-id-type="pmcid">PMC1280127</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oechslin</surname><given-names>F</given-names></name><name name-style="western"><surname>Daraspe</surname><given-names>J</given-names></name><name name-style="western"><surname>Giddey</surname><given-names>M</given-names></name><name name-style="western"><surname>Moreillon</surname><given-names>P</given-names></name><name name-style="western"><surname>Resch</surname><given-names>G</given-names></name></person-group><article-title>In vitro characterization of PlySK1249, a novel phage lysin, and assessment of its antibacterial activity in a mouse model of <italic toggle="yes">Streptococcus agalactiae</italic> bacteremia</article-title><source>Antimicrob Agents Chemother</source><year>2013</year><volume>57</volume><fpage>6276</fpage><lpage>6283</lpage><pub-id pub-id-type="pmid">24100496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01701-13</pub-id><pub-id pub-id-type="pmcid">PMC3837886</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Oechslin F, Daraspe J, Giddey M, Moreillon P, Resch G (2013) In vitro characterization of PlySK1249, a novel phage lysin, and assessment of its antibacterial activity in a mouse model of <italic toggle="yes">Streptococcus agalactiae</italic> bacteremia. Antimicrob Agents Chemother 57:6276&#8211;6283<pub-id pub-id-type="pmid">24100496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01701-13</pub-id><pub-id pub-id-type="pmcid">PMC3837886</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>A</given-names></name><name name-style="western"><surname>Hawkins</surname><given-names>CH</given-names></name><name name-style="western"><surname>Anggard</surname><given-names>EE</given-names></name><name name-style="western"><surname>Harper</surname><given-names>DR</given-names></name></person-group><article-title>A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant <italic toggle="yes">Pseudomonas aeruginosa</italic>; a preliminary report of efficacy</article-title><source>Clin Otolaryngol</source><year>2009</year><volume>34</volume><fpage>349</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">19673983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1749-4486.2009.01973.x</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Wright A, Hawkins CH, Anggard EE, Harper DR (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant <italic toggle="yes">Pseudomonas aeruginosa</italic>; a preliminary report of efficacy. Clin Otolaryngol 34:349&#8211;357<pub-id pub-id-type="pmid">19673983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1749-4486.2009.01973.x</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>